#	Pagina
attuale pagina	/open-h2020/projects/207218/index.html

Opendata, web and dolomites

MultiViVax SIGNED

Development of Effective Vaccines against Multiple Lifecycle Stages of Plasmodium vivax malaria

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

MultiViVax project word cloud

Explore the words cloud of the MultiViVax project. It provides you a very rough idea of what is the project "MultiViVax" about.

humans remove parasites efforts critical 2030 vitro 75 pipeline candidates asia efficacy accounts advantage oceania successful first lack progress multivivax global screening transgenic calls parasite indication people health curve 400 human chmi proportion culture time immuno lifecycle inability utilise america million constitutes stage roadmap despite clinical vivax interventions intervention risk bottleneck shift billion transmission caused vaccine blood plasmodium severity lagged latin multiple revised stages weighted select protective equally assays recognises safe infection rnaseq vaccines living falciparum immunity overcome malaria model antigens bottlenecks prioritise

Project "MultiViVax" data sheet

The following table provides information about the project.

Coordinator	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD Organization address address: WELLINGTON SQUARE UNIVERSITY OFFICES city: OXFORD postcode: OX1 2JD website: www.ox.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	United Kingdom [UK]
Project website	http://www.multivivax.eu
Total cost	5˙763˙405 €
EC max contribution	5˙058˙974 € (88%)
Programme	1. H2020-EU.3.1.2. (Preventing disease)
Code Call	H2020-SC1-2016-RTD
Funding Scheme	RIA
Starting year	2017
Duration (year-month-day)	from 2017-01-01 to 2021-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD Organization address address: WELLINGTON SQUARE UNIVERSITY OFFICES city: OXFORD postcode: OX1 2JD website: www.ox.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (OXFORD)	coordinator	4˙526˙425.00
2	GENOME RESEARCH LIMITED GENOME RESEARCH LIMITED Organization address address: THE GIBBS BUILDING, EUSTON ROAD 215 city: LONDON postcode: NW1 2BE website: http://www.sanger.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (LONDON)	participant	351˙298.00
3	NOVAVAX AB NOVAVAX AB Organization address address: KUNGSGATAN 109 city: UPPSALA postcode: 753 18 website: www.isconova.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (UPPSALA)	participant	56˙250.00
4	OSIVAX SAS OSIVAX SAS Organization address address: 4 RUE DE COPENHAGUE city: PARIS postcode: 75008 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	35˙873.00
5	INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT Organization address address: BOULEVARD DE DUNKERQUE 44 CS 90009 city: MARSEILLE postcode: 13572 website: www.ird.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (MARSEILLE)	participant	30˙000.00
6	THE UNIVERSITY OF EDINBURGH THE UNIVERSITY OF EDINBURGH Organization address address: OLD COLLEGE, SOUTH BRIDGE city: EDINBURGH postcode: EH8 9YL website: www.ed.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (EDINBURGH)	participant	30˙000.00
7	EXPRES2ION BIOTECHNOLOGIES APS EXPRES2ION BIOTECHNOLOGIES APS Organization address address: AGERN ALLE 1 city: HORSHOLM postcode: 2970 website: www.expres2ionbio.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DK (HORSHOLM)	participant	25˙000.00
8	IMAXIO SA IMAXIO SA Organization address address: RUE SAINT ROCH 5/7 city: PARIS postcode: 75001 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	4˙126.00

Map

Project objective

Plasmodium vivax is the most widespread malaria and constitutes a significant proportion of human malaria cases. P. vivax accounts for 100-400 million clinical cases each year among the 2.5 billion people living at risk in Latin America, Oceania and Asia. The recently revised Malaria Vaccine Technology Roadmap to 2030 recognises the severity of P. vivax malaria and calls for a vaccine intervention to achieve 75% efficacy over two years – equally weighted with P. falciparum. However, despite this global health need, efforts to develop interventions against this parasite have lagged far behind those for P. falciparum, in large part because of critical bottlenecks in the vaccine development process. These include i) lack of assays to prioritise and down-select new vaccines due to lack of an in vitro P. vivax long-term culture system, and ii) lack of easy access to a safe controlled human malaria infection (CHMI) model to provide an early indication of vaccine efficacy in humans. The Objectives of this MultiViVax proposal will address these critical bottlenecks and shift the “risk curve” in order to better select successful vaccine candidates against multiple lifecycle stages of P. vivax:

1. We will establish a P. vivax CHMI model in Europe for the first time to facilitate the better selection of effective vaccines and remove the current bottleneck for their early-phase clinical testing.

2. We will utilise this CHMI model to identify novel antigens associated with protective blood-stage immunity in humans by taking advantage of recent advances in immuno-screening and parasite RNASeq.

3. We will progress existing vaccines targeting the current leading antigens for both the blood- and transmission-stages along the clinical development pipeline.

4. We will develop novel transgenic parasites for use in assays in order to overcome the current bottleneck in vaccine down-selection caused by the inability to culture P. vivax parasites.

Deliverables

List of deliverables.
Generation and fitness assessment of transgenic parasite Pf-Pvs25	Documents, reports	2020-01-27 12:28:09
Description of website	Websites, patent fillings, videos etc.	2020-01-27 12:28:09

Take a look to the deliverables list in detail: detailed list of MultiViVax deliverables.

Publications

List of publications.
year	authors and title	journal	last update
2019	Thomas. A. Rawlinson, Natalie M. Barber, Franziska Mohring, Jee Sun Cho, Varakorn Kosaisavee, Samuel F. GÃ©rard, Daniel G. W. Alanine, GeneviÃ¨ve M. LabbÃ©, Sean C. Elias, Sarah E. Silk, Doris Quinkert, Jing Jin, Jennifer M. Marshall, Ruth O. Payne, Angela M. Minassian, Bruce Russell, Laurent RÃ©nia, FranÃ§ois H. Nosten, Robert W. Moon, Matthew K. Higgins, Simon J. Draper Structural basis for inhibition of Plasmodium vivax invasion by a broadly neutralizing vaccine-induced human antibody published pages: 1497-1507, ISSN: 2058-5276, DOI: 10.1038/s41564-019-0462-1	Nature Microbiology 4/9	2020-03-05

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MULTIVIVAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MULTIVIVAX" are provided by the European Opendata Portal: CORDIS opendata.